Skip to main content
Home Licenses

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

See what’s new.

https://otc.duke.edu/wp-content/uploads/2023/09/menarini-stemline-logos.png

European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

ORSERDU is based on technology licensed out of the lab of Dr. Donald McDonnell (Pharmacology and Cancer Biology, SOM).

Read More

https://otc.duke.edu/wp-content/uploads/2023/01/11B5C88A-E824-48AC-B630-1E8815D4E436.jpg

Durham-based Restor3d raises $17 million

restor3d, a Duke spinout from the lab of Prof Ken Gall (MEMS, Pratt), is also a Duke Capital Partners portfolio company.

Read More

https://otc.duke.edu/wp-content/uploads/2023/09/aspirion-acquires-infinia-ml-featured-image.png

Aspirion Acquires Infinia ML, an established leader in AI and Machine Learning

Infinia ML is a Duke artificial intelligence start-up spun out of the lab of Professor Lawrence Carin (ECE, Pratt).

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/Sparta_Biomedical__Logo.jpg

Sparta Biomedical Closes an Oversubscribed Convertible Round to Advance its Breakthrough Device

Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry,…

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/Sparta_Biomedical__Logo.jpg

Sparta Biomedical Celebrates Prestigious Recognition in MedTech and Significant Milestone

Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry,…

Read More

https://otc.duke.edu/wp-content/uploads/2022/09/Precision-Biosciences.jpeg

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

Precision BioSciences, a genome editing Duke spin-out, was founded by then-postdocs Jeff Smith and Derek Jantz (Biochemistry, SOM).

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/zhou_pei_HERO2.jpg

Synthetic Antibiotic Could Be Effective Against Drug-Resistant Superbugs

Decades of work by a series of Duke investigators yields new drug, patents and a startup company Valanbio Therapeutics

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/clinetic-logo.png

Clinetic Announces Series A Funding Round Led by Sopris Capital

Clinetic is a medical records Duke start-up founded on technology developed by a team at the Duke Institute for Health Innovation

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/Benner-Study-01@0.25x.png

Newly Identified Lipid in Breast Milk Might Reduce Cerebral Palsy in Infants

Tellus Therapeutics, a neonatal white matter injury therapeutics start-up, was co-founded by Dr. Eric Brenner (Pediatrics, SOM)

Read More

1 2 3 8